Insider buying last 90 days
No open-market insider purchases were filed for RPRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RPRX insider filing, plotted on the chart in Gekko.Open RPRX in Gekko
NASDAQ: RPRX
Royalty Pharma (RPRX) Stock Analysis & Forecast
Sep 28 close
$58.37+0.16 (+0.3%)
Gekko Brief
AI summaryRoyalty Pharma has drawn attention this week for its broader strategic outlook, with executives discussing plans to expand artificial-intelligence capabilities and build a presence in China while navigating a shifting biopharma policy environment and maintaining discipline around capital deployment and leverage. The company also presented at the Bank of America Global Healthcare Conference 2026. Separately, an EVP sold 100,000 shares for approximately $5.85 million under a pre-arranged trading plan, and a holder has filed to sell an additional 100,000 shares worth about $5.8 million.
Shares closed at $58.37, up 0.3%, sitting between the 50-day average of $59.46 and the 200-day average of $50.69, reflecting a mixed trend picture. The GekkoIndex reads 61.6, placing RPRX in the Accumulation zone. The stock trades 14% above Gekko Fair Value of $51.2.
The next earnings date falls on 4 November 2026, before the open, which lies outside a typical 20-trading-day holding window. There is one billionaire holder on record, while insider, Congress and options activity show no signals in their respective windows. Seasonality over the past 5 years shows an average 20-day return of 0.5% from this point in the calendar, positive in 3 of those years. Analyst consensus from 7 firms remains at a buy rating with a target of $65.12.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Royalty Pharma price vs fair value
Close $58.37200-day averageGekko Fair Value $51.20
Royalty Pharma quick facts
- Market cap
- $25.87B
- P/E ratio
- 31
- Forward P/E
- 29.4
- EPS, TTM
- $1.88
- Revenue, TTM
- $2.54B
- Profit margin
- 32%
- Dividend yield
- 1.58%
- Beta
- 0.43
- Volume
- 1.86M avg 3.28M
- 1-year return
- +67.2%
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±3.8%
- 50-day average
- $59.46
- 200-day average
- $50.69
- Next earnings
- Nov 4 before open
- Shares outstanding
- 445.3M
Royalty Pharma swing-trade checklist
Royalty Pharma scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $58.37 sits between the 50-day ($59.46) and 200-day ($50.69) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
61.6, Accumulation
Reading 61.6 is in the Accumulation zone.
See the GekkoIndex - Fair valueheadwind
14.0% above
Price is 14% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.5% on average
From this point in the calendar, the next 20 trading days averaged +0.5% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Royalty Pharma stock chart and price history
Royalty Pharma closed at $58.37 on Sep 28, 2026, +67.2% over the past year, inside a 52-week range of $34.63 to $64.38.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −5.7%
- 3 months
- +2.2%
- 6 months
- +25.9%
- 1 year
- +67.2%
The full RPRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RPRX in Gekko
Follow Royalty Pharma through every session
Put RPRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RPRX in GekkoFree for 7 days. No credit card required.
Royalty Pharma GekkoIndex: the smart money zone
Royalty Pharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.6, in the Accumulation zone, down 1.4 points over five sessions.
61.6Accumulation
Down 1.4 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 24 | +1.5% | +5.4% | ||
| Accumulation (current zone) | 140 | +0.1% | +1.9% | ||
| Neutral | 441 | +0.7% | +2.3% | ||
| Distribution | 65 | +0.1% | +2.9% | ||
| Selling | 2 | Too few readings yet | |||
Average RPRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the RPRX price, zone by zone.Track RPRX in Gekko
Is Royalty Pharma stock overvalued? Gekko Fair Value
Royalty Pharma trades 14.0% above Gekko Fair Value of $51.20, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Royalty Pharma shares are worth, recalculated every trading day.
$51.20
Gekko Fair Value, Sep 26, 2026
14.0% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open RPRX in Gekko
Royalty Pharma insider and Congress trading
No open-market insider purchases were filed for Royalty Pharma, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RPRX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RPRX, plotted on the chart in Gekko.Open RPRX in Gekko
Buybacks
Royalty Pharma has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $44.64M
- As a share of market cap
- 0.17%
- Trailing four quarters
- $321.8M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds RPRX.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Royalty Pharma earnings: next date and track record
Royalty Pharma reports on Nov 4, 2026, before the open (36 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 36 days away
- EPS estimate
- $1.18
- Revenue estimate
- $877.4M
7 of 8reports beat the EPS estimate
±2.8%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, May 6, 2026 AI summary
- What they said
- Royalty Pharma reported strong Q1 2026 results with 10% portfolio receipts growth and 13% royalty receipts growth. ROIC was ~14% and return on invested equity ~20%. The company deployed $1.25B in announced transactions across 3 therapies, repurchased 1M shares for $50M, and raised its dividend 7%. Key portfolio highlights include positive Phase III data for daraxonrasib in pancreatic cancer and FDA approval of Avlayah in Hunter syndrome.
- Guidance
- Management raised full-year 2026 guidance based on strong Q1 momentum. The company is expanding R&D co-funding partnerships, targeting a market with over $1 trillion in projected global biopharma R&D spend over the next 5 years.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 6, 2026 | $1.30 est $1.18 | $925.0M est $881.7M | −0.5% |
| Feb 11, 2026 | $1.46 est $1.29 | $874.0M est $807.0M | +1.3% |
| Nov 5, 2025 | $1.17 est $0.99 | $609.3M est $717.4M | +7.8% |
| Aug 6, 2025 | $1.14 est $1.03 | $578.7M est $673.0M | −2.4% |
| May 8, 2025 | $1.06 est $0.95 | $568.2M est $705.3M | +1.2% |
| Feb 11, 2025 | $1.15 est $1.05 | $594.0M est $687.1M | +2.0% |
| Nov 6, 2024 | $1.04 est $0.93 | $564.7M est $696.9M | −3.7% |
| Aug 8, 2024 | $0.96 est $0.97 | $537.3M est $627.4M | −3.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Royalty Pharma stock forecast and analyst price targets
Analysts’ average 12-month price target for Royalty Pharma is $65.12, +11.6% from the last close, from 7 firms rating the stock in the last 90 days.
$65.12consensus 12-month target, +11.6% from the last close
Now $58.37Avg $65.12
Low $62High $70
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 23 | Bank of America Securities | $63 | +7.9% |
| Sep 9 | Citi | $70 | +19.9% |
| Sep 8 | UBS | $66 | +13.1% |
| Sep 8 | TD Cowen | $68 | +16.5% |
| Sep 8 | Bank of America Securities | $63 | +7.9% |
+1.9%average 20-day move after past Accumulation readings
+0.5%average move over the next 20 trading days in the last 5 years
±2.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Royalty Pharma seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Royalty Pharma averaged +0.5% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.1% | 2 of 5 |
| Next 10 trading days | +0.7% | 3 of 5 |
| Next 15 trading days | +1.6% | 4 of 5 |
| Next 20 trading days | +0.5% | 3 of 5 |
| Next 30 trading days | +5.0% | 4 of 5 |
For scale, RPRX’s typical 20-trading-day move in either direction is about 3.8%.
Royalty Pharma market cap and key statistics
Royalty Pharma’s market cap is $25.87B, with a P/E ratio of 31 and revenue of $2.54B over the last twelve months.
Valuation
- Market cap
- $25.87B
- P/E ratio
- 31
- Forward P/E
- 29.4
- EPS, TTM
- $1.88
- Gekko Fair Value
- $51.20
Trading
- Volume
- 1.86M
- Avg volume, 20 days
- 3.28M
- 52-week high
- $64.38
- 52-week low
- $34.63
- Shares outstanding
- 445.3M
Financials
- Revenue, TTM
- $2.54B
- Profit margin
- 32%
- Return on equity
- 14%
- Quarterly earnings growth, YoY
- −46.3%
Risk and income
- Beta
- 0.43
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±3.8%
- Dividend yield
- 1.58%
Royalty Pharma stock news this week
Coverage of Royalty Pharma this week reads neutral: 0 positive, 3 neutral and 0 negative headlines.
- Royalty Pharma (NASDAQ:RPRX) Stock: Insider Christopher Hite Sells 100,000 SharesDefense World, Sep 26
- Royalty Pharma EVP Christopher Hite sells $5.85m in sharesInvesting.com, Sep 25
- Form 4 Royalty Pharma Plc For: 25 September By Investing.comInvesting.com Canada, Sep 25
- Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy ShiftsMarketBeat, Sep 25
- Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?The Motley Fool, Sep 24
- Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha, Sep 23
Royalty Pharma peers
Royalty Pharma’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Royalty Pharma stock FAQ
What is Royalty Pharma’s market cap?
Royalty Pharma’s market cap is $25.87B at the Sep 28, 2026 close of $58.37, with 445.3M shares outstanding. The shares trade on a P/E ratio of 31.
What is the Royalty Pharma stock forecast?
The consensus analyst 12-month price target for Royalty Pharma is $65.12, +11.6% from the last close. Of the 7 firms that rated the stock in the last 90 days, 7 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Royalty Pharma stock overvalued or undervalued?
On Gekko’s estimate Royalty Pharma is overvalued: the Sep 28, 2026 close of $58.37 is 14.0% above Gekko Fair Value of $51.20. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Royalty Pharma report earnings next?
Royalty Pharma is expected to report on Nov 4, 2026, before the market opens (36 days away). Analysts expect earnings of $1.18 per share on revenue of $877.4M. Royalty Pharma beat the earnings estimate in 7 of its last 8 reports, moving 2.8% on average across the report.
What is Royalty Pharma’s 52-week high and low?
Royalty Pharma’s 52-week high is $64.38 and its 52-week low is $34.63; it closed at $58.37 on Sep 28, 2026, +67.2% over the past year.
Is Royalty Pharma stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, earnings risk and seasonality), 1 as mixed (trend) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Royalty Pharma the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.